Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG

Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, et al. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell. 2019;36:528–544 e10.

NOTES

Anastas, Jamie NZee, Barry MKalin, Jay HKim, MirheeGuo, RobynAlexandrescu, SandaBlanco, Mario AndresGiera, StefanieGillespie, Shawn MDas, JayantaWu, MuzhouNocco, SarahBonal, Dennis MNguyen, Quang-DeSuva, Mario LBernstein, Bradley EAlani, RhodaGolub, Todd RCole, Philip AFilbin, Mariella GShi, YangengR35 CA210104/CA/NCI NIH HHS/F32 CA189741/CA/NCI NIH HHS/P30 CA006516/CA/NCI NIH HHS/F32 GM108364/GM/NIGMS NIH HHS/R37 GM062437/GM/NIGMS NIH HHS/Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tCancer Cell. 2019 Nov 11;36(5):528-544.e10. doi: 10.1016/j.ccell.2019.09.005. Epub 2019 Oct 17.

Abstract

H3K27M mutations resulting in epigenetic dysfunction are frequently observed in diffuse intrinsic pontine glioma (DIPGs), an incurable pediatric cancer. We conduct a CRISPR screen revealing that knockout of KDM1A encoding lysine-specific demethylase 1 (LSD1) sensitizes DIPG cells to histone deacetylase (HDAC) inhibitors. Consistently, Corin, a bifunctional inhibitor of HDACs and LSD1, potently inhibits DIPG growth in vitro and in xenografts. Mechanistically, Corin increases H3K27me3 levels suppressed by H3K27M histones, and simultaneously increases HDAC-targeted H3K27ac and LSD1-targeted H3K4me1 at differentiation-associated genes. Corin treatment induces cell death, cell-cycle arrest, and a cellular differentiation phenotype and drives transcriptional changes correlating with increased survival time in DIPG patients. These data suggest a strategy for treating DIPG by simultaneously inhibiting LSD1 and HDACs.
Last updated on 02/17/2021